Last reviewed · How we verify
NCT05858190
Drug-eluting Balloon for Treatment of Non-atherosclerotic Renal Artery Stenosis--a Multicenter Study
NA trial testing Parallel Assignment in Hypertension, Renovascular in 90 participants. Not yet recruiting.
1 June 2026
Quick facts
| Lead sponsor | Peking Union Medical College Hospital |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 90 |
| Start date | 1 June 2023 |
| Primary completion | 1 June 2026 |
| Estimated completion | 1 December 2026 |
Drugs / interventions tested
- Parallel Assignment
Conditions studied
- Hypertension, Renovascular — all drugs for Hypertension, Renovascular →
Sponsor
Peking Union Medical College Hospital
Who can join
Adults 18 to 45, any sex, with Hypertension, Renovascular. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study will test the efficacy of drug eluting balloon(DEB) for non-atherosclerotic renal artery stenosis. The DEB (paclitaxel eluting balloon) will be used in the intervention group, while the plain old balloon(POB) will be used in the control group. The primary outcome is the effect of blood pressure control.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Drug-coated balloon for treatment of non-atherosclerotic renal artery stenosis-a multi-center study.
Song X, Fu Y, Lai Z, Di X, et al · · 2023 · PMID 37845604 · DOI 10.1186/s12872-023-03484-5
Verify or expand the search:
- PubMed search for NCT05858190
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Parallel Assignment
Trials testing the same drug.
- NCT04719741 — Drug and Dose Adjustment in Preventing Postoperative Nausea and Vomiting · unknown
- NCT04546542 — Hydroxychloroquine Blood Levels in Primary Sjögren Syndrome Patients · completed
Other Peking Union Medical College Hospital trials
Trials by the same sponsor.
- NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
- NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
- NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
- NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
- NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05858190 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
- Last refreshed: 15 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05858190.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing